- Home
- APCX vs CANF Comparison
APCX vs CANF Comparison
Compare APCX & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APCX
- CANF
- Stock Information
- Founded
- APCX 2006
- CANF 1994
- Country
- APCX United States
- CANF Israel
- Employees
- APCX N/A
- CANF N/A
- Industry
- APCX Finance: Consumer Services
- CANF Biotechnology: Pharmaceutical Preparations
- Sector
- APCX Finance
- CANF Health Care
- Exchange
- APCX Nasdaq
- CANF Nasdaq
- Market Cap
- APCX N/A
- CANF 14.4M
- IPO Year
- APCX N/A
- CANF N/A
- Fundamental
- Price
- APCX $0.60
- CANF $1.48
- Analyst Decision
- APCX
- CANF Strong Buy
- Analyst Count
- APCX 0
- CANF 2
- Target Price
- APCX N/A
- CANF $14.00
- AVG Volume (30 Days)
- APCX 10.6M
- CANF 1.2M
- Earning Date
- APCX 11-14-2024
- CANF 12-31-2024
- Dividend Yield
- APCX N/A
- CANF N/A
- EPS Growth
- APCX N/A
- CANF N/A
- EPS
- APCX N/A
- CANF N/A
- Revenue
- APCX $365,000.00
- CANF $667,000.00
- Revenue This Year
- APCX $1,315.48
- CANF $409.56
- Revenue Next Year
- APCX N/A
- CANF N/A
- P/E Ratio
- APCX N/A
- CANF N/A
- Revenue Growth
- APCX N/A
- CANF N/A
- 52 Week Low
- APCX $0.31
- CANF $1.29
- 52 Week High
- APCX $2.30
- CANF $4.69
- Technical
- Relative Strength Index (RSI)
- APCX 60.21
- CANF 35.58
- Support Level
- APCX $0.36
- CANF $1.30
- Resistance Level
- APCX $1.49
- CANF $1.72
- Average True Range (ATR)
- APCX 0.14
- CANF 0.18
- MACD
- APCX 0.02
- CANF -0.01
- Stochastic Oscillator
- APCX 24.32
- CANF 17.92
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).